NMLSF Stock Chart & Stats
$0.06
-$0.01(-18.16%)
At close: 4:00 PM EDT
$0.06
-$0.01(-18.16%)
Day’s Range― - ―
52-Week Range$0.01 - $0.12
Previous CloseN/A
Volume1.02K
Average Volume (3M)1.30K
Market Cap
$3.70M
Enterprise Value$2.50M
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$354.09K
Price to Earnings (P/E)―
Beta3.49
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding61,077,354
10 Day Avg. Volume3,456
30 Day Avg. Volume1,296
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue18.59
Enterprise Value/Gross Profit-23.01
Enterprise Value/Ebitda-3.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementThe shift to positive equity in 2025 and modest leverage materially reduces immediate solvency risk and improves financing optionality. Over a 2–6 month horizon this structural improvement strengthens the company's ability to raise capital on better terms, sustain operations, and execute near-term R&D or partnership milestones.
Rebuilding Asset BaseAn expanding asset base signals reinvestment into the business (IP, inventory, or equipment) and provides tangible backing for operations. This structural restoration supports future commercialization or research efforts, helps collateralize financing, and underpins operational capacity across the next several months.
Improving Cash Burn TrendA materially reduced negative operating and free cash flow trend indicates better cost control or progress toward monetization. While still negative, the improvement extends runway and lowers near-term funding pressure, making the company more resilient and better positioned to reach milestones or negotiate financing over the coming months.
Bears Say
No Recurring RevenueA lack of recurring revenue shows the business model has not produced sustainable sales, leaving operational funding dependent on external capital or one-time events. This structural deficiency heightens execution risk and means the company must demonstrate durable revenue generation to achieve self-sufficiency in the 2–6 month window.
Persistent Operating Losses And Negative FCFChronic operating losses and negative free cash flow erode capital and necessitate repeated financing, limiting strategic flexibility. Even with recent improvements, continued cash burn is a structural weakness that constrains R&D investment, partnerships, and ability to scale without dilution or higher-cost capital.
Historical Equity VolatilityPrior periods of negative equity reflect past solvency stress and raise questions about balance-sheet stability. That history can impede access to favorable capital, increase counterparties' caution, and raise dilution risk—structural impediments that can limit growth and financing options over the medium term.
Restart Life Sciences News
NMLSF FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was $0.01 and its highest was $0.12 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is $3.70M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Aug 21, 2026 which is in 17 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 61,077,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in NMLSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.